Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2023

Open Access 12-05-2023 | Prolactinoma | Case report

A giant invasive macroprolactinoma with recurrent nasal bleeding as the first clinical presentation: case report and review of literature

Authors: Danting Li, Yan Wang, Huiwen Tan, Peiqiong Luo, Yerong Yu

Published in: BMC Endocrine Disorders | Issue 1/2023

Login to get access

Abstract

Background

Giant prolactinoma (> 4 cm in dimension) is a rare disorder. Invasive macroprolactinoma has the potential to cause base of skull erosion and extend into the nasal cavity or even the sphenoid sinus. Nasal bleeding caused by intranasal tumor extension is a rare complication associated with invasive giant prolactinoma.
We report a case of giant invasive macroprolactinoma with repeated nasal bleeding as the initial symptom.

Case presentation

A 24-year-old man with an invasive giant prolactinoma in the nasal cavity and sellar region who presented with nasal bleeding as the initial symptom, misdiagnosed as olfactory neuroblastoma. However, markedly elevated serum prolactin levels (4700 ng/mL), and a 7.8-cm invasive sellar mass confirmed the diagnosis of invasive giant prolactinoma. He was treated with oral bromocriptine. Serum prolactin was reduced to near normal after 6 months of treatment. Follow-up magnetic resonance imaging showed that the sellar lesion had disappeared completely and the skull base lesions were reduced.

Conclusion

This case is notable in demonstrating the aggressive nature of untreated invasive giant prolactinomas which can cause a diagnostic difficulty with potential serious consequences. Early detection of hormonal levels can avoid unnecessary nasal biopsy. Early identification of pituitary adenoma with nasal bleeding as the first symptom is particularly important.
Appendix
Available only for authorised users
Literature
1.
go back to reference Blackmon MM, Gilbert AR, Floyd J, Hafeez S, Seifi A. Lost to follow-up: complications of an invasive giant prolactinoma. Cureus. 2020;12(8):e9763.PubMedPubMedCentral Blackmon MM, Gilbert AR, Floyd J, Hafeez S, Seifi A. Lost to follow-up: complications of an invasive giant prolactinoma. Cureus. 2020;12(8):e9763.PubMedPubMedCentral
2.
go back to reference Shrivastava RK, Arginteanu MS, King WA, Post KD. Giant prolactinomas: clinical management and long-term follow up. J Neurosurg. 2002;97(2):299–306.CrossRefPubMed Shrivastava RK, Arginteanu MS, King WA, Post KD. Giant prolactinomas: clinical management and long-term follow up. J Neurosurg. 2002;97(2):299–306.CrossRefPubMed
3.
go back to reference Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, Colosimo C. Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol (Oxf). 2003;58(5):662–70.CrossRefPubMed Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, Colosimo C. Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol (Oxf). 2003;58(5):662–70.CrossRefPubMed
4.
go back to reference Iglesias P, Arcano K, Berrocal VR, Bernal C, Villabona C, Diez JJ. Giant prolactinoma in men: clinical features and therapeutic outcomes. Horm Metab Res. 2018;50(11):791–6.CrossRefPubMed Iglesias P, Arcano K, Berrocal VR, Bernal C, Villabona C, Diez JJ. Giant prolactinoma in men: clinical features and therapeutic outcomes. Horm Metab Res. 2018;50(11):791–6.CrossRefPubMed
5.
go back to reference Hamidi O, Van Gompel J, Gruber L, Kittah NE, Donegan D, Philbrick KA, Koeller KK, Erickson D, Natt N, Nippoldt TB, Young WF Jr, Bancos I. Management and outcomes of giant prolactinoma: a series of 71 patients. Endocr Pract. 2019;25(4):340–52.CrossRefPubMed Hamidi O, Van Gompel J, Gruber L, Kittah NE, Donegan D, Philbrick KA, Koeller KK, Erickson D, Natt N, Nippoldt TB, Young WF Jr, Bancos I. Management and outcomes of giant prolactinoma: a series of 71 patients. Endocr Pract. 2019;25(4):340–52.CrossRefPubMed
6.
go back to reference Shimon I, Benbassat C. Male prolactinomas presenting with normal testosterone levels. Pituitary. 2014;17(3):246–50.CrossRefPubMed Shimon I, Benbassat C. Male prolactinomas presenting with normal testosterone levels. Pituitary. 2014;17(3):246–50.CrossRefPubMed
7.
go back to reference Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab. 2008;93(12):4721–7.CrossRefPubMed Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab. 2008;93(12):4721–7.CrossRefPubMed
8.
go back to reference Sibal L, Ugwu P, Kendall-Taylor P, Ball SG, James RA, Pearce SH, Hall K, Quinton R. Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function. Pituitary. 2002;5(4):243–6.CrossRefPubMed Sibal L, Ugwu P, Kendall-Taylor P, Ball SG, James RA, Pearce SH, Hall K, Quinton R. Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function. Pituitary. 2002;5(4):243–6.CrossRefPubMed
9.
go back to reference van der Mey AG, van Seters AP, van Krieken JH, Vielvoye J, van Dulken H, Hulshof JH. Large pituitary adenomas with extension into the nasopharynx. Report of three cases with a review of the literature. Ann Otol Rhinol Laryngol. 1989;98(8 Pt 1):618–24.PubMed van der Mey AG, van Seters AP, van Krieken JH, Vielvoye J, van Dulken H, Hulshof JH. Large pituitary adenomas with extension into the nasopharynx. Report of three cases with a review of the literature. Ann Otol Rhinol Laryngol. 1989;98(8 Pt 1):618–24.PubMed
10.
go back to reference Hofman R, Franken AA, Rosingh HJ. Just epistaxis? Neth J Med. 2010;68(5):227–30.PubMed Hofman R, Franken AA, Rosingh HJ. Just epistaxis? Neth J Med. 2010;68(5):227–30.PubMed
11.
go back to reference Chaurasia PK, Singh D, Meher S, Saran RK, Singh H. Epistaxis as first clinical presentation in a child with giant prolactinoma: case report and review of literature. J Pediatr Neurosci. 2011;6(2):134–7.PubMedPubMedCentral Chaurasia PK, Singh D, Meher S, Saran RK, Singh H. Epistaxis as first clinical presentation in a child with giant prolactinoma: case report and review of literature. J Pediatr Neurosci. 2011;6(2):134–7.PubMedPubMedCentral
12.
go back to reference Sahoo JP, Kamalanathan S, Parida PK, Pillai V. A giant prolactinoma with nasopharyngeal extension presenting with nasal blockage and epistaxis. BMJ Case Rep. 2015;2015:bcr2014208811.CrossRefPubMedPubMedCentral Sahoo JP, Kamalanathan S, Parida PK, Pillai V. A giant prolactinoma with nasopharyngeal extension presenting with nasal blockage and epistaxis. BMJ Case Rep. 2015;2015:bcr2014208811.CrossRefPubMedPubMedCentral
13.
go back to reference Imamura J, Okuzono T, Okuzono Y. Fatal epistaxis caused by rupture of an intratumoral aneurysm enclosed by a large prolactinoma–case report. Neurol Med Chir (Tokyo). 1998;38(10):654–6.CrossRefPubMed Imamura J, Okuzono T, Okuzono Y. Fatal epistaxis caused by rupture of an intratumoral aneurysm enclosed by a large prolactinoma–case report. Neurol Med Chir (Tokyo). 1998;38(10):654–6.CrossRefPubMed
14.
go back to reference Godey B, Morandi X, Le Gall F, Feat S, Brassier G, Le Clech G. Pituitary adenomas with infra-sellar extension into the nasopharynx. J Laryngol Otol. 1999;113(12):1109–11.CrossRefPubMed Godey B, Morandi X, Le Gall F, Feat S, Brassier G, Le Clech G. Pituitary adenomas with infra-sellar extension into the nasopharynx. J Laryngol Otol. 1999;113(12):1109–11.CrossRefPubMed
15.
go back to reference Kleinschmidt-DeMasters BK, Lillehei KO. Pathological correlates of pituitary adenomas presenting with apoplexy. Hum Pathol. 1998;29(11):1255–65.CrossRefPubMed Kleinschmidt-DeMasters BK, Lillehei KO. Pathological correlates of pituitary adenomas presenting with apoplexy. Hum Pathol. 1998;29(11):1255–65.CrossRefPubMed
16.
go back to reference Ghannam NN, Hammami MM, Muttair Z, Bakheet SM. Primary hypothyroidism-associated TSH-secreting pituitary adenoma/hyperplasia presenting as a bleeding nasal mass and extremely elevated TSH level. J Endocrinol Invest. 1999;22(6):419–23.CrossRefPubMed Ghannam NN, Hammami MM, Muttair Z, Bakheet SM. Primary hypothyroidism-associated TSH-secreting pituitary adenoma/hyperplasia presenting as a bleeding nasal mass and extremely elevated TSH level. J Endocrinol Invest. 1999;22(6):419–23.CrossRefPubMed
17.
go back to reference Das CJ, Seith A, Gamanagatti S, Goswami R. On the AJR viewbox. Ectopic pituitary adenoma with an empty sella. AJR Am J Roentgenol. 2006;186(5):1468–9.CrossRefPubMed Das CJ, Seith A, Gamanagatti S, Goswami R. On the AJR viewbox. Ectopic pituitary adenoma with an empty sella. AJR Am J Roentgenol. 2006;186(5):1468–9.CrossRefPubMed
18.
go back to reference Vilar L, Vilar CF, Lyra R, Freitas MDC. Pitfalls in the diagnostic evaluation of hyperprolactinemia. Neuroendocrinology. 2019;109(1):7–19.CrossRefPubMed Vilar L, Vilar CF, Lyra R, Freitas MDC. Pitfalls in the diagnostic evaluation of hyperprolactinemia. Neuroendocrinology. 2019;109(1):7–19.CrossRefPubMed
19.
go back to reference Raverot V, Perrin P, Chanson P, Jouanneau E, Brue T, Raverot G. Prolactin immunoassay: does the high-dose hook effect still exist? Pituitary. 2022;25(4):653–7.CrossRefPubMed Raverot V, Perrin P, Chanson P, Jouanneau E, Brue T, Raverot G. Prolactin immunoassay: does the high-dose hook effect still exist? Pituitary. 2022;25(4):653–7.CrossRefPubMed
20.
go back to reference Huang HY, Zhai W, Tang H, Hui GZ, Wu ZB. Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas. Endocrine. 2018;62(2):464–9.CrossRefPubMed Huang HY, Zhai W, Tang H, Hui GZ, Wu ZB. Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas. Endocrine. 2018;62(2):464–9.CrossRefPubMed
21.
go back to reference Trouillas J, Jaffrain-Rea ML, Vasiljevic A, Raverot G, Roncaroli F, Villa C. How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020. Cancers (Basel). 2020;12(2):514.CrossRefPubMed Trouillas J, Jaffrain-Rea ML, Vasiljevic A, Raverot G, Roncaroli F, Villa C. How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020. Cancers (Basel). 2020;12(2):514.CrossRefPubMed
22.
go back to reference Hyrcza MD, Ezzat S, Mete O, Asa SL. Pituitary adenomas presenting as sinonasal or nasopharyngeal masses: a case series illustrating potential diagnostic pitfalls. Am J Surg Pathol. 2017;41(4):525–34.CrossRefPubMed Hyrcza MD, Ezzat S, Mete O, Asa SL. Pituitary adenomas presenting as sinonasal or nasopharyngeal masses: a case series illustrating potential diagnostic pitfalls. Am J Surg Pathol. 2017;41(4):525–34.CrossRefPubMed
23.
go back to reference van der Lely AJ, Knegt PP, Stefanko SZ, Tanghe HL, Singh R, Lamberts SW. Nasopharyngeal presentation of pituitary tumors. Differential diagnosis and treatment. J Clin Endocrinol Metab. 1992;74(4):811–3.CrossRefPubMed van der Lely AJ, Knegt PP, Stefanko SZ, Tanghe HL, Singh R, Lamberts SW. Nasopharyngeal presentation of pituitary tumors. Differential diagnosis and treatment. J Clin Endocrinol Metab. 1992;74(4):811–3.CrossRefPubMed
25.
go back to reference ZamanipoorNajafabadi AH, Zandbergen IM, de Vries F, Broersen LHA, van den Akker-van Marle ME, Pereira AM, Peul WC, Dekkers OM, van Furth WR, Biermasz NR. Surgery as a viable alternative first-line treatment for prolactinoma patients a systematic review and meta-analysis. J Clin Endocrinol Metab. 2020;105(3):e32-41.CrossRef ZamanipoorNajafabadi AH, Zandbergen IM, de Vries F, Broersen LHA, van den Akker-van Marle ME, Pereira AM, Peul WC, Dekkers OM, van Furth WR, Biermasz NR. Surgery as a viable alternative first-line treatment for prolactinoma patients a systematic review and meta-analysis. J Clin Endocrinol Metab. 2020;105(3):e32-41.CrossRef
26.
go back to reference Shimon I, Benbassat C, Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol. 2007;156(2):225–31.CrossRefPubMed Shimon I, Benbassat C, Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol. 2007;156(2):225–31.CrossRefPubMed
27.
go back to reference Moraes AB, Silva CM, Vieira Neto L, Gadelha MR. Giant prolactinomas: the therapeutic approach. Clin Endocrinol (Oxf). 2013;79(4):447–56.CrossRefPubMed Moraes AB, Silva CM, Vieira Neto L, Gadelha MR. Giant prolactinomas: the therapeutic approach. Clin Endocrinol (Oxf). 2013;79(4):447–56.CrossRefPubMed
28.
go back to reference Maiter D, Delgrange E. Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol. 2014;170(6):R213-227.CrossRefPubMed Maiter D, Delgrange E. Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol. 2014;170(6):R213-227.CrossRefPubMed
29.
go back to reference Liu X, Tang C, Wen G, Zhong C, Yang J, Zhu J, Ma C. The mechanism and pathways of dopamine and dopamine agonists in prolactinomas. Front Endocrinol. 2018;9:768.CrossRef Liu X, Tang C, Wen G, Zhong C, Yang J, Zhu J, Ma C. The mechanism and pathways of dopamine and dopamine agonists in prolactinomas. Front Endocrinol. 2018;9:768.CrossRef
30.
go back to reference Aslan K, Bekci T, Incesu L, Özdemir M. Giant invasive basal skull prolactinoma with CSF rhinorrhoea and meningitis. Clin Neurol Neurosurg. 2014;120:145–6.CrossRefPubMed Aslan K, Bekci T, Incesu L, Özdemir M. Giant invasive basal skull prolactinoma with CSF rhinorrhoea and meningitis. Clin Neurol Neurosurg. 2014;120:145–6.CrossRefPubMed
31.
go back to reference Chng E, Dalan R. Pituitary apoplexy associated with cabergoline therapy. J Clin Neurosci. 2013;20(12):1637–43.CrossRefPubMed Chng E, Dalan R. Pituitary apoplexy associated with cabergoline therapy. J Clin Neurosci. 2013;20(12):1637–43.CrossRefPubMed
32.
go back to reference Cesak T, Poczos P, Adamkov J, Nahlovsky J, Kasparova P, Gabalec F, Celakovsky P, Choutka O. Medically induced CSF rhinorrhea following treatment of macroprolactinoma: case series and literature review. Pituitary. 2018;21(6):561–70.CrossRefPubMed Cesak T, Poczos P, Adamkov J, Nahlovsky J, Kasparova P, Gabalec F, Celakovsky P, Choutka O. Medically induced CSF rhinorrhea following treatment of macroprolactinoma: case series and literature review. Pituitary. 2018;21(6):561–70.CrossRefPubMed
Metadata
Title
A giant invasive macroprolactinoma with recurrent nasal bleeding as the first clinical presentation: case report and review of literature
Authors
Danting Li
Yan Wang
Huiwen Tan
Peiqiong Luo
Yerong Yu
Publication date
12-05-2023

Other articles of this Issue 1/2023

BMC Endocrine Disorders 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine